INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of June 30, 2017 and December 31, 2016:

	June 30, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(7,488	)	$	24,463		12.25
Development costs of  corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,207,267		(135,282	)	$	1,071,985		15.5
Hormone therapy drug candidate patents (pending)		1,444,581		—			1,444,581		n/a
Non-amortizing intangible assets:
Multiple trademarks		198,657		—			198,657		indefinite
Total	$	2,974,199	$	(234,513	)	$	2,739,686

	December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(6,490	)	$	25,461		12.75
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,093,452		(102,393	)		991,059		16
Hormone therapy drug candidate patents (pending)		1,203,987		—			1,203,987		n/a
Non-amortizing intangible assets:
Multiple trademarks		185,465		—			185,465		indefinite
Total	$	2,606,598	$	(200,626	)	$	2,405,972

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:

Year Ending December 31,		Estimated Amortization
	2017(6 months)	$	35,579
	2018	$	71,157
	2019	$	71,157
	2020	$	71,157
	2021	$	71,157
	Thereafter	$	776,241